Future prospects in the treatment of erectile dysfunction: focus on avanafil

被引：28

作者：

Alwaal, Amjad ^{[1
]}

Al-Mannie, Raed ^{[1
]}

Carrier, Serge ^{[1
]}

机构：

[1] McGill Univ, Div Urol, Ctr Hlth, Montreal, PQ, Canada

来源：

DRUG DESIGN DEVELOPMENT AND THERAPY | 2011年 / 5卷

关键词：

PDE5; sexual performance; pharmacokinetics; RABBIT CORPUS CAVERNOSUM; PHOSPHODIESTERASE TYPE-5 INHIBITOR; PENILE PROSTHESIS IMPLANTATION; SOLUBLE GUANYLATE-CYCLASE; HEALTHY MALE-SUBJECTS; NITRIC-OXIDE; SILDENAFIL CITRATE; DOUBLE-BLIND; RHO-KINASE; PHARMACOLOGICAL PROFILE;

D O I：

10.2147/DDDT.S15852

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The treatment of erectile dysfunction (ED) has been revolutionized in the last 15 years with the introduction of type 5 phosphodiesterase (PDE5) inhibitors. Their efficacy, safety, and ease of administration have made them first-line treatment for ED. This article reviews the current therapies available for ED, and the new PDE5 inhibitors that are being investigated. Furthermore, it examines all the current ED treatment options that are in different phases of development (including oral and topical pharmacotherapy, gene therapy, and tissue engineering). A special emphasis is on avanafil, a new PDE5 inhibitor that has been studied extensively in Phase I and II clinical trials and has undergone several Phase III trials. Avanafil is a promising medication for ED due to its favorable pharmacokinetics, safety, and efficacy.

引用

页码：435 / 443

页数：9

共 77 条

[1]

Andersson KE, 2001, PHARMACOL REV, V53, P417

[2]

[Anonymous], 2011, 47 EASD ANN M 13 SEP

[3] 5-hydroxytryptamine2C receptors on spinal neurons controlling penile erection in the rat [J].